Olartan-Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil selectively antagonizes the angiotensin II type 1 (AT₁) receptor, preventing angiotensin II‑induced vasoconstriction and aldosterone secretion. By inhibiting this pathway, it reduces peripheral vascular resistance and fluid retention, contributing to a sustained decrease in systolic and diastolic blood pressure.

The dosage of Olartan-Plus is individualized by the prescribing physician based on the patient’s blood pressure, renal function, and response to therapy. The prescriber determines the appropriate strength and frequency, and any adjustments are made during follow‑up visits to achieve target blood pressure while minimizing adverse effects.

The safety of Olartan-Plus in pregnancy has not been established, and it is generally avoided because ARBs may cause fetal toxicity. Likewise, limited data exist for use while breastfeeding; therefore, the medication should only be used if the potential benefit outweighs the possible risk to the infant, under medical supervision.

To request Olartan-Plus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides a quotation, availability, shipping details—including any special handling—and the necessary import documentation.

Compared with monotherapy using either an ARB or a thiazide diuretic alone, Olartan-Plus offers combined blood‑pressure reduction in a single tablet, which can improve adherence and provide greater efficacy in patients whose pressure is not controlled by a single agent. It is generally considered when guideline‑recommended step‑up therapy is needed, while maintaining a safety profile similar to its individual components.

Olartan-Plus tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the medication in its original blister pack or container, protect it from moisture and direct sunlight, and ensure it is out of reach of children. Do not store in a refrigerator or freezer unless otherwise directed by the supplier.

Olartan-Plus is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or split unless the prescriber specifically advises. Consistent timing each day helps maintain stable blood‑pressure control.

The most serious adverse events linked to Olartan-Plus include severe hypotension, acute kidney injury, hyperkalemia, and allergic reactions such as angioedema or rash. Patients should be monitored for signs of excessive blood‑pressure lowering, renal dysfunction, electrolyte disturbances, and hypersensitivity, and should seek immediate medical attention if any of these symptoms occur.

Olartan-Plus is contraindicated in individuals with known hypersensitivity to olmesartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in patients with severe renal impairment, hyperkalemia, or those taking other potassium‑sparing agents. Pregnant women and nursing mothers should not use it unless the potential benefit justifies the risk, and it is generally not recommended for children.